Last $5.12 USD
Change Today -0.07 / -1.35%
Volume 49.2K
CBRX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

columbia laboratories inc (CBRX) Key Developments

Columbia Laboratories Inc. Approves Amendments to Articles of Incorporation

On January 9, 2015, the Board of Directors of Columbia Laboratories Inc. approved an amendment to Article I, Section 9 of the company’s Amended and Restated By-Laws to change the voting standard for uncontested elections of directors to a majority of votes cast from a plurality standard.

Columbia Laboratories, Inc. Appoints Bridget A. Martell as Chief Medical Officer

Columbia Laboratories Inc. announced the appointment of Dr. Bridget A. Martell to the newly created position of Chief Medical Officer, effective immediately. Dr. Martell brings more than 15 years' experience in clinical development, medical affairs and academia to Columbia, including expertise in establishing regulatory strategy for clinical programs and creating submission readiness packages. Most recently, Dr. Martell was the founder and managing director of BAM Consultants, which provides clinical development and medical affairs consulting services to a broad array of specialty pharmaceutical companies.

Columbia Laboratories Inc. Presents at Benchmark's Micro Cap Discovery One-on-One Conference, Dec-11-2014

Columbia Laboratories Inc. Presents at Benchmark's Micro Cap Discovery One-on-One Conference, Dec-11-2014 . Venue: The Palmer House Hilton, 17 E. Monroe, Chicago, IL 60603, United States.

Columbia Laboratories Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Revenue Guidance for the Year 2014

Columbia Laboratories Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's total net revenues were $11,463,000 compared to $7,126,000 a year ago. The increase reflects higher product and service revenues in addition to a one-time benefit from the sale of intellectual property rights and technology for Legatrin P.M., which contributed $2.2 million to revenues. Income from operations was $3,512,000 compared to $1,267,000 a year ago. Income before income taxes was $3,560,000 compared to $1,721,000 a year ago. Net income was $3,670,000 or $0.34 per diluted share compared to $1,718,000 or $0.11 per diluted share a year ago. Adjusted EBITDA was $4,488,000 compared to $2,484,000 a year ago. Cash flow from operations generated during the three month period ended September 30, 2014 was $5.1 million. For the nine months, the company's total net revenues were $25,568,000 compared to $21,419,000 a year ago. Income from operations was $3,918,000 compared to $5,108,000 a year ago. Income before income taxes was $4,360,000 compared to $5,625,000 a year ago. Net income was $4,292,000 or $0.34 per diluted share compared to $5,617,000 or $0.46 per diluted share a year ago. Adjusted EBITDA was $6,267,000 compared to $7,833,000 a year ago. Including the $2.2 million contribution from the Legatrin P.M. sale, the company now expects full year 2014 revenue growth of 14% to 16%.

Columbia Laboratories Inc., Q3 2014 Earnings Call, Oct 28, 2014

Columbia Laboratories Inc., Q3 2014 Earnings Call, Oct 28, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBRX:US $5.12 USD -0.07

CBRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.86 USD -0.63
View Industry Companies
 

Industry Analysis

CBRX

Industry Average

Valuation CBRX Industry Range
Price/Earnings 11.0x
Price/Sales 1.7x
Price/Book 1.3x
Price/Cash Flow 10.3x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLUMBIA LABORATORIES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.